Iovance Biotherapeutics Inc (LTS:0JDK)
$ 11.29 0.295 (2.68%) Market Cap: 3.48 Bil Enterprise Value: 3.15 Bil PE Ratio: 0 PB Ratio: 4.43 GF Score: 30/100

Q4 2019 Iovance Biotherapeutics Inc Earnings Call Transcript

Feb 25, 2020 / 09:30PM GMT
Release Date Price: $23.68
Operator

Good afternoon, and welcome to the Iovance Biotherapeutics Fourth Quarter and Year-end 2019 Financial Results Conference Call. (Operator Instructions) Please be advised that the call is being recorded at the company's request.

Now I would like to turn the call over to Sara Pellegrino, Vice President, Investor and Public Relations at Iovance. Please go ahead.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, Laurie. Good afternoon, everyone, and thank you for joining us. Speaking on today's call will be Maria Fardis, our President and Chief Executive Officer; Friedrich Finckenstein, our Chief Medical Officer; and Tim Morris, Chief Financial Officer.

This afternoon, we issued a press release that can be found on our website at iovance.com, which includes the financial results for the fourth quarter and year ended December 31, 2019, as well as a corporate update.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot